# Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

> **NCT00560495** · PHASE1 · WITHDRAWN · sponsor: **Roswell Park Cancer Institute**

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** ammonium tetrathiomolybdate
- **OTHER:** immunoenzyme technique
- **OTHER:** laboratory biomarker analysis
- **RADIATION:** Tc 99m sestamibi
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00560495
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2007-05
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2022-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00560495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00560495, "Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00560495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*